• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MEB
Click for more information
12.5% 0.9¢

MEDIBIO LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MEB Investor Presentation22/03/19
MEB Medibio Limited Shareholder Update and Outlook21/03/19
MEB Change in substantial holding19/03/19
MEB Ceasing to be a substantial holder18/03/19
MEB MEB Announces Completion of Entitlement Issue14/03/19
MEB MEB Outsources Psychology Services in support of ilumenPRICE SENSITIVE14/03/19
MEB Entitlement Issue Results and Shortfall NotificationPRICE SENSITIVE12/03/19
MEB Ilumen Successfully Completes First Commercial ProgramPRICE SENSITIVE07/03/19
MEB Half Yearly Report and AccountsPRICE SENSITIVE28/02/19
MEB Extension to Entitlement Offer - Correction26/02/19
MEB Medibio Announces Extension to Entitlement Offer25/02/19
MEB Initial Director's Interest Notice - M Leydin22/02/19
MEB Final Director's Interest Notice - A Maxwell22/02/19
MEB Changes to the Board of Directors & Appointment of Chairman22/02/19
MEB Investor Presentation - February 201914/02/19
MEB Extension of Entitlement Offer04/02/19
MEB Medibio Quarterly Update and Cashflow ReportPRICE SENSITIVE31/01/19
MEB Cleansing Notice and Appendix 3B31/01/19
MEB Results of General Meeting21/01/19
MEB Addendum to Notice of General Meeting07/01/19
MEB Initial Director's Interest Notice04/01/19
MEB Final Director's Interest Notice04/01/19
MEB Medibio announces board changes and cost reduction plans24/12/18
MEB Notice of General Meeting/Proxy Form21/12/18
MEB Entitlement Offer BookletPRICE SENSITIVE18/12/18
MEB Cleansing Notice and Appendix 3B18/12/18
MEB Letter to Ineligible Shareholders - Entitlement Offer11/12/18
MEB Letter to Shareholders - Entitlement Offer11/12/18
MEB Notification of Pro-Rata Non-Renounceable Entitlement Issue10/12/18
MEB Section 708AA(2)(F) Cleansing Statement and Appendix 3B10/12/18
MEB Investor Presentation10/12/18
MEB Converting Note & Non-Renounceable Entitlement OfferPRICE SENSITIVE10/12/18
MEB Trading HaltPRICE SENSITIVE06/12/18
MEB Pause in TradingPRICE SENSITIVE06/12/18
MEB Investor Presentation28/11/18
MEB Exclusive Agreement Signed for ilumen Pilot ProgramPRICE SENSITIVE27/11/18
MEB Appointment of Joint Company Secretary16/11/18
MEB Results of Annual General Meeting16/11/18
MEB Chairman's Address to Shareholders16/11/18
MEB Response to ASX Appendix 4C QueryPRICE SENSITIVE15/11/18
MEB Change of Director's Interest Notice14/11/18
MEB Medibio Provides Update on FDA ProcessPRICE SENSITIVE09/11/18
MEB Change of Director's Interest Notice x208/11/18
MEB Initial Director's Interest Notice08/11/18
MEB Medibio Appoints CEO and Managing DirectorPRICE SENSITIVE02/11/18
MEB Medibio Market UpdatePRICE SENSITIVE02/11/18
MEB Medibio Quarterly Update and Cashflow ReportPRICE SENSITIVE30/10/18
MEB MEB Signs ilumen Contract with Large Australian EmployerPRICE SENSITIVE24/10/18
MEB Notice of Annual General Meeting/Proxy Form16/10/18
MEB Receipt of R&D Tax Incentive RefundPRICE SENSITIVE15/10/18
MEB MEB Presentations - Mayo Clinic Convergence Neuroscience08/10/18
MEB Investor Presentation05/10/18
MEB Medibio Releases Corporate Health Product, ilumenPRICE SENSITIVE03/10/18
MEB Notice of Initial Substantial Holder02/10/18
MEB Notice Received Under Section 249D of the Corporations ActPRICE SENSITIVE01/10/18
MEB Annual Report to shareholders27/09/18
MEB Final Director's Interest Notice21/09/18
MEB Executive Leadership ChangesPRICE SENSITIVE21/09/18
MEB Appendix 4G & Corporate Governance Statement14/09/18
MEB Annual Report to shareholders14/09/18
MEB Medibio Market Update10/09/18
MEB Medibio Hosts Call to Discuss Clinical Validation Study07/09/18
MEB Clinical Study Shows Improvement to Diagnostic StandardPRICE SENSITIVE06/09/18
MEB Preliminary Final ReportPRICE SENSITIVE30/08/18
MEB Departure of Managing Director & Chief Executive OfficerPRICE SENSITIVE29/08/18
MEB Trading HaltPRICE SENSITIVE28/08/18
MEB Pause in TradingPRICE SENSITIVE28/08/18
MEB Medibio Quarterly Update and Cashflow ReportPRICE SENSITIVE31/07/18
MEB MEB to announce fourth quarter FY18 results (Updated)31/07/18
MEB MEB to announce fourth quarter FY18 results30/07/18
MEB Medibio Submits FDA De Novo ApplicationPRICE SENSITIVE16/07/18 download Created with Sketch. 104.57KB
MEB Medibio Science published in EC Neurology27/06/18 download Created with Sketch. 171.12KB
MEB Change of Director's Interest Notices x621/06/18 download Created with Sketch. 287.95KB
MEB Appendix 3B21/06/18 download Created with Sketch. 239.54KB
MEB Medibio Receives TGA ApprovalPRICE SENSITIVE19/06/18 download Created with Sketch. 131.54KB
MEB Medibio to provide Corporate Health Investor Presentation18/06/18 download Created with Sketch. 8.04MB
MEB Medibio provides updated Investor Presentation12/06/18 download Created with Sketch. 13.77MB
MEB Company Secretary Appointment/Resignation06/06/18 download Created with Sketch. 93.07KB
MEB Results of Meeting06/06/18 download Created with Sketch. 249.63KB
MEB MEB Signs Global Contract with Jacobs EngineeringPRICE SENSITIVE25/05/18 download Created with Sketch. 203.19KB
MEB Medibio Announces Next Tranche of Corporate Health ContractsPRICE SENSITIVE10/05/18
MEB Medibio Signs First Corporate Health ContractPRICE SENSITIVE09/05/18
MEB Notice of Extraordinary General Meeting/Proxy Form07/05/18
MEB Medibio Receives CE CertificationPRICE SENSITIVE03/05/18
MEB Medibio Announces Global Corporate Mental Health Launch01/05/18
MEB Medibio Quarterly Update and Cashflow ReportPRICE SENSITIVE30/04/18
MEB MEB to announce third quarter FY18 update and cashflow27/04/18
MEB Medibio Announces Scientific Advisory Board26/04/18
MEB Appendix 3B & S708 cleansing notice17/04/18
MEB Medibio completes Vital Conversation acquisition12/04/18
MEB Change in substantial holding11/04/18
MEB Appendix 3B and S708 cleansing statement05/03/18
MEB MEB signs binding term sheet to acquire Vital ConversationsPRICE SENSITIVE05/03/18
MEB Investor Update05/03/18
MEB Half Yearly Report and AccountsPRICE SENSITIVE27/02/18
MEB Medibio Quarterly Update and Cash Flow ReportPRICE SENSITIVE31/01/18
MEB MEB to announce second quarter FY18 update and cashflow30/01/18
MEB Final Director's Interest Notice22/01/18
MEB Agreement with Striiv to Accelerate CommercialisationPRICE SENSITIVE22/01/18
MEB Peter Carlisle Appointed as Director22/01/18
MEB Investor Presentation
22/03/19
MEB Medibio Limited Shareholder Update and Outlook
21/03/19
MEB Change in substantial holding
19/03/19
MEB Ceasing to be a substantial holder
18/03/19
MEB MEB Announces Completion of Entitlement Issue
14/03/19
MEB MEB Outsources Psychology Services in support of ilumen
14/03/19PRICE SENSITIVE
MEB Entitlement Issue Results and Shortfall Notification
12/03/19PRICE SENSITIVE
MEB Ilumen Successfully Completes First Commercial Program
07/03/19PRICE SENSITIVE
MEB Half Yearly Report and Accounts
28/02/19PRICE SENSITIVE
MEB Extension to Entitlement Offer - Correction
26/02/19
MEB Medibio Announces Extension to Entitlement Offer
25/02/19
MEB Initial Director's Interest Notice - M Leydin
22/02/19
MEB Final Director's Interest Notice - A Maxwell
22/02/19
MEB Changes to the Board of Directors & Appointment of Chairman
22/02/19
MEB Investor Presentation - February 2019
14/02/19
MEB Extension of Entitlement Offer
04/02/19
MEB Medibio Quarterly Update and Cashflow Report
31/01/19PRICE SENSITIVE
MEB Cleansing Notice and Appendix 3B
31/01/19
MEB Results of General Meeting
21/01/19
MEB Addendum to Notice of General Meeting
07/01/19
MEB Initial Director's Interest Notice
04/01/19
MEB Final Director's Interest Notice
04/01/19
MEB Medibio announces board changes and cost reduction plans
24/12/18
MEB Notice of General Meeting/Proxy Form
21/12/18
MEB Entitlement Offer Booklet
18/12/18PRICE SENSITIVE
MEB Cleansing Notice and Appendix 3B
18/12/18
MEB Letter to Ineligible Shareholders - Entitlement Offer
11/12/18
MEB Letter to Shareholders - Entitlement Offer
11/12/18
MEB Notification of Pro-Rata Non-Renounceable Entitlement Issue
10/12/18
MEB Section 708AA(2)(F) Cleansing Statement and Appendix 3B
10/12/18
MEB Investor Presentation
10/12/18
MEB Converting Note & Non-Renounceable Entitlement Offer
10/12/18PRICE SENSITIVE
MEB Trading Halt
06/12/18PRICE SENSITIVE
MEB Pause in Trading
06/12/18PRICE SENSITIVE
MEB Investor Presentation
28/11/18
MEB Exclusive Agreement Signed for ilumen Pilot Program
27/11/18PRICE SENSITIVE
MEB Appointment of Joint Company Secretary
16/11/18
MEB Results of Annual General Meeting
16/11/18
MEB Chairman's Address to Shareholders
16/11/18
MEB Response to ASX Appendix 4C Query
15/11/18PRICE SENSITIVE
MEB Change of Director's Interest Notice
14/11/18
MEB Medibio Provides Update on FDA Process
09/11/18PRICE SENSITIVE
MEB Change of Director's Interest Notice x2
08/11/18
MEB Initial Director's Interest Notice
08/11/18
MEB Medibio Appoints CEO and Managing Director
02/11/18PRICE SENSITIVE
MEB Medibio Market Update
02/11/18PRICE SENSITIVE
MEB Medibio Quarterly Update and Cashflow Report
30/10/18PRICE SENSITIVE
MEB MEB Signs ilumen Contract with Large Australian Employer
24/10/18PRICE SENSITIVE
MEB Notice of Annual General Meeting/Proxy Form
16/10/18
MEB Receipt of R&D Tax Incentive Refund
15/10/18PRICE SENSITIVE
MEB MEB Presentations - Mayo Clinic Convergence Neuroscience
08/10/18
MEB Investor Presentation
05/10/18
MEB Medibio Releases Corporate Health Product, ilumen
03/10/18PRICE SENSITIVE
MEB Notice of Initial Substantial Holder
02/10/18
MEB Notice Received Under Section 249D of the Corporations Act
01/10/18PRICE SENSITIVE
MEB Annual Report to shareholders
27/09/18
MEB Final Director's Interest Notice
21/09/18
MEB Executive Leadership Changes
21/09/18PRICE SENSITIVE
MEB Appendix 4G & Corporate Governance Statement
14/09/18
MEB Annual Report to shareholders
14/09/18
MEB Medibio Market Update
10/09/18
MEB Medibio Hosts Call to Discuss Clinical Validation Study
07/09/18
MEB Clinical Study Shows Improvement to Diagnostic Standard
06/09/18PRICE SENSITIVE
MEB Preliminary Final Report
30/08/18PRICE SENSITIVE
MEB Departure of Managing Director & Chief Executive Officer
29/08/18PRICE SENSITIVE
MEB Trading Halt
28/08/18PRICE SENSITIVE
MEB Pause in Trading
28/08/18PRICE SENSITIVE
MEB Medibio Quarterly Update and Cashflow Report
31/07/18PRICE SENSITIVE
MEB MEB to announce fourth quarter FY18 results (Updated)
31/07/18
MEB MEB to announce fourth quarter FY18 results
30/07/18
MEB Medibio Submits FDA De Novo Application
16/07/18PRICE SENSITIVE download Created with Sketch. 104.57KB
MEB Medibio Science published in EC Neurology
27/06/18 download Created with Sketch. 171.12KB
MEB Change of Director's Interest Notices x6
21/06/18 download Created with Sketch. 287.95KB
MEB Appendix 3B
21/06/18 download Created with Sketch. 239.54KB
MEB Medibio Receives TGA Approval
19/06/18PRICE SENSITIVE download Created with Sketch. 131.54KB
MEB Medibio to provide Corporate Health Investor Presentation
18/06/18 download Created with Sketch. 8.04MB
MEB Medibio provides updated Investor Presentation
12/06/18 download Created with Sketch. 13.77MB
MEB Company Secretary Appointment/Resignation
06/06/18 download Created with Sketch. 93.07KB
MEB Results of Meeting
06/06/18 download Created with Sketch. 249.63KB
MEB MEB Signs Global Contract with Jacobs Engineering
25/05/18PRICE SENSITIVE download Created with Sketch. 203.19KB
MEB Medibio Announces Next Tranche of Corporate Health Contracts
10/05/18PRICE SENSITIVE
MEB Medibio Signs First Corporate Health Contract
09/05/18PRICE SENSITIVE
MEB Notice of Extraordinary General Meeting/Proxy Form
07/05/18
MEB Medibio Receives CE Certification
03/05/18PRICE SENSITIVE
MEB Medibio Announces Global Corporate Mental Health Launch
01/05/18
MEB Medibio Quarterly Update and Cashflow Report
30/04/18PRICE SENSITIVE
MEB MEB to announce third quarter FY18 update and cashflow
27/04/18
MEB Medibio Announces Scientific Advisory Board
26/04/18
MEB Appendix 3B & S708 cleansing notice
17/04/18
MEB Medibio completes Vital Conversation acquisition
12/04/18
MEB Change in substantial holding
11/04/18
MEB Appendix 3B and S708 cleansing statement
05/03/18
MEB MEB signs binding term sheet to acquire Vital Conversations
05/03/18PRICE SENSITIVE
MEB Investor Update
05/03/18
MEB Half Yearly Report and Accounts
27/02/18PRICE SENSITIVE
MEB Medibio Quarterly Update and Cash Flow Report
31/01/18PRICE SENSITIVE
MEB MEB to announce second quarter FY18 update and cashflow
30/01/18
MEB Final Director's Interest Notice
22/01/18
MEB Agreement with Striiv to Accelerate Commercialisation
22/01/18PRICE SENSITIVE
MEB Peter Carlisle Appointed as Director
22/01/18
refresh Created with Sketch. REFRESH
 

Top Stories

'Taking money from the market': Garbage giant cleans up as this week's Hot Stock tip

Wealth Within chief analyst Dale Gillham and senior analyst Fil Tortevski have tipped $4.68 billion garbage giant Cleanaway Waste Management Limited (ASX:CWY) as their Hotcopper Hot Stock tip of the week @ especially because it seems to be slowly building towards a euphoric run akin to its mid 20...
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.